CHA₂DS₂-VASc Score Calculator - AF Stroke Risk

About CHA₂DS₂-VASc

The CHA₂DS₂-VASc score was developed by Lip et al. (2010) to improve upon the original CHADS₂ score for stroke risk stratification in atrial fibrillation. The acronym stands for: Congestive heart failure, Hypertension, Age ≥75 (×2), Diabetes, Stroke/TIA (×2), Vascular disease, Age 65–74, Sex category (female). Maximum score is 9. The score underpins the 2020 European Society of Cardiology atrial fibrillation guidelines (a focused update was published in 2024).

ESC 2020 Anticoagulation Thresholds

Score	Males	Females	Recommendation
0 (male) / 1 (female, sex only)	0	1 (sex only)	No antithrombotic therapy, low risk
1 (male) / 2 (female)	1	2	Consider anticoagulation, weigh benefit/risk
≥2 (male) / ≥3 (female)	≥2	≥3	Anticoagulation recommended, DOAC preferred

Important: Female sex alone (score = 1 for female, score = 0 without other risk factors) is not an independent risk factor. A female with CHA₂DS₂-VASc of 1 (sex only) has a very low absolute risk and anticoagulation is generally not indicated. Several of the point-scoring criteria above, hypertension, diabetes, and vascular disease, are also core inputs to general cardiovascular risk tools such as the Framingham Risk Score, reflecting how much stroke and cardiovascular risk overlap in practice.

DOAC vs Warfarin

For non-valvular AF where anticoagulation is indicated, DOACs (direct oral anticoagulants, apixaban, rivaroxaban, edoxaban, dabigatran) are preferred over warfarin per ESC 2020, ACC/AHA 2019, and NICE NG196 guidelines. Exceptions include significant mitral stenosis and prosthetic heart valves, where warfarin remains the standard of care.

HAS-BLED Bleeding Risk

CHA₂DS₂-VASc should be used alongside a bleeding risk assessment. The HAS-BLED score (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history, Labile INR, Elderly ≥65, Drugs/alcohol) identifies patients at high bleeding risk, checking Creatinine Clearance covers the renal-function half of that component and also determines whether a DOAC needs dose adjustment. However, most bleeding risk factors are also stroke risk factors, a high HAS-BLED score should prompt modification of reversible risk factors (hypertension control, medication review), not reflexively withhold anticoagulation.

Frequently Asked Questions

Should female sex alone (score 1) lead to anticoagulation?+

No. A female patient with CHA₂DS₂-VASc of 1 arising solely from her sex (no other risk factors) has a very low absolute stroke risk. ESC 2020 guidelines explicitly state that female sex alone does not indicate anticoagulation. The score of 1 for females functions as a modifier, it only becomes clinically significant when combined with at least one other stroke risk factor, resulting in a total score ≥2.

Can CHA₂DS₂-VASc be used for paroxysmal AF?+

Yes. The thromboembolic risk in paroxysmal AF is comparable to persistent or permanent AF at similar CHA₂DS₂-VASc scores. Current guidelines do not differentiate anticoagulation recommendations by AF type (paroxysmal vs persistent vs permanent), the CHA₂DS₂-VASc score applies equally to all forms of non-valvular AF.

Does CHA₂DS₂-VASc apply to valvular AF?+

No. CHA₂DS₂-VASc applies to non-valvular AF only. "Valvular AF" in the context of anticoagulation specifically means AF associated with moderate-to-severe mitral stenosis or mechanical prosthetic heart valves, these patients require warfarin (vitamin K antagonist) regardless of their CHA₂DS₂-VASc score, as DOACs are not licensed for this indication.

Related Tools on MediCalc Pro

For DVT/PE pre-test probability and anticoagulation indication, see Wells Score. For ACS risk stratification, see TIMI Score and HEART Score. For neurological assessment in stroke, see Glasgow Coma Scale.

References

Lip GY, et al. "Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation." Chest. 2010;137(2):263-272.
Hindricks G, et al. "2020 ESC Guidelines for the diagnosis and management of atrial fibrillation." Eur Heart J. 2021;42(5):373-498.
January CT, et al. "2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation." JACC. 2019;74(1):104-132.
NICE Guideline NG196. Atrial fibrillation: diagnosis and management. NICE, 2021.

⚠️ Medical Disclaimer: The CHA₂DS₂-VASc score guides anticoagulation decisions but does not replace comprehensive clinical assessment. All prescribing decisions must be made by a qualified physician incorporating individual patient circumstances, comorbidities, bleeding risk, and patient preference.